KRYS
Price
$132.73
Change
+$0.70 (+0.53%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.82B
67 days until earnings call
PRTA
Price
$5.06
Change
+$0.18 (+3.69%)
Updated
Jun 5, 04:36 PM (EDT)
Capitalization
262.68M
63 days until earnings call
Interact to see
Advertisement

KRYS vs PRTA

Header iconKRYS vs PRTA Comparison
Open Charts KRYS vs PRTABanner chart's image
Krystal Biotech
Price$132.73
Change+$0.70 (+0.53%)
Volume$6.21K
Capitalization3.82B
Prothena
Price$5.06
Change+$0.18 (+3.69%)
Volume$1.45K
Capitalization262.68M
KRYS vs PRTA Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. PRTA commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and PRTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (KRYS: $132.03 vs. PRTA: $4.88)
Brand notoriety: KRYS and PRTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 65% vs. PRTA: 77%
Market capitalization -- KRYS: $3.82B vs. PRTA: $262.68M
KRYS [@Biotechnology] is valued at $3.82B. PRTA’s [@Biotechnology] market capitalization is $262.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • PRTA’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 6 TA indicator(s) are bullish while PRTA’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 6 bullish, 2 bearish.
  • PRTA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than PRTA.

Price Growth

KRYS (@Biotechnology) experienced а +7.03% price change this week, while PRTA (@Biotechnology) price change was +6.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

PRTA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.82B) has a higher market cap than PRTA($263M). KRYS YTD gains are higher at: -15.722 vs. PRTA (-64.765). KRYS has higher annual earnings (EBITDA): 140M vs. PRTA (-137.71M). KRYS has more cash in the bank: 617M vs. PRTA (418M). KRYS has less debt than PRTA: KRYS (9.66M) vs PRTA (10.2M). KRYS has higher revenues than PRTA: KRYS (333M) vs PRTA (138M).
KRYSPRTAKRYS / PRTA
Capitalization3.82B263M1,451%
EBITDA140M-137.71M-102%
Gain YTD-15.722-64.76524%
P/E Ratio31.66N/A-
Revenue333M138M241%
Total Cash617M418M148%
Total Debt9.66M10.2M95%
FUNDAMENTALS RATINGS
KRYS vs PRTA: Fundamental Ratings
KRYS
PRTA
OUTLOOK RATING
1..100
42
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
5790
PRICE GROWTH RATING
1..100
8997
P/E GROWTH RATING
1..100
9794
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (56) in the Biotechnology industry is in the same range as KRYS (70) in the Pharmaceuticals Major industry. This means that PRTA’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for PRTA (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than PRTA’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for PRTA (90) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than PRTA’s over the last 12 months.

KRYS's Price Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as PRTA (97) in the Biotechnology industry. This means that KRYS’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's P/E Growth Rating (94) in the Biotechnology industry is in the same range as KRYS (97) in the Pharmaceuticals Major industry. This means that PRTA’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSPRTA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 15 days ago
76%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGFNX9.11N/A
N/A
MassMutual Global R3
NMVZX11.89N/A
N/A
Nuance Mid Cap Value Z
CGLAX17.53N/A
N/A
Calvert Global Equity Fund Class A
JHLVX51.73N/A
N/A
JHancock Fundamental Large Cap Core C
CLCRX22.42N/A
N/A
Columbia Select Large Cap Equity Inst2

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
+1.04%
RCKT - PRTA
54%
Loosely correlated
-1.35%
DNLI - PRTA
44%
Loosely correlated
+3.52%
KRYS - PRTA
40%
Loosely correlated
+0.86%
RVMD - PRTA
39%
Loosely correlated
-0.49%
AXON - PRTA
38%
Loosely correlated
+2.76%
More